MabPlex Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
667
- Latest Deal Type
-
IPO
- (Cancelled)
- Investors
-
19
MabPlex General Information
Description
Provider of contract development and manufacturing services intended to offer comprehensive services from drug development to drug manufacturing. The company offers contract services from DNA to finished drug product and manufactures monoclonal antibodies (MABs), recombinant proteins, Antibody drugs (ADCs) and bispecific, enabling customers to receive high quality solutions for bio-manufacturing.
Contact Information
Website
www.mabplexinc.comCorporate Office
- 60 Middle Beijing Road
- Yantai Development Zone, Pilot Free Trade Zone
- Yantai, Shandong 264006
- China
Corporate Office
- 60 Middle Beijing Road
- Yantai Development Zone, Pilot Free Trade Zone
- Yantai, Shandong 264006
- China
MabPlex Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. IPO | 16-Feb-2025 | Cancelled | Profitable | |||
| 5. Secondary Transaction - Private | 08-Jun-2020 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series B) | 01-Jun-2020 | Completed | Generating Revenue | |||
| 3. Secondary Transaction - Private | 29-May-2020 | Completed | Generating Revenue | |||
| 2. Later Stage VC (Series A) | 01-Nov-2018 | $56.4M | $56.4M | Completed | Generating Revenue | |
| 1. Joint Venture | 25-Jun-2013 | Completed | Generating Revenue |
MabPlex Comparisons
Industry
Financing
Details
MabPlex Competitors (16)
One of MabPlex’s 16 competitors is Lonza Group, a Corporation company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lonza Group | Corporation | Basel, Switzerland | ||||
| Bellen Chemistry | Venture Capital-Backed | Beijing, China | ||||
| KBI BioPharma | Formerly VC-backed | Durham, NC | ||||
| AAPharmaSyn | Corporation | Ann Arbor, MI | ||||
| Fujifilm Diosynth Biotechnologies | Corporate Backed or Acquired | College Station, TX |
MabPlex Patents
MabPlex Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240408226-A1 | Antibody drug conjugate intermediate containing sn38 and its preparation method | Pending | 02-Nov-2021 | ||
| AU-2022383308-A1 | Antibody-drug conjugate intermediate comprising sn38 and preparation method therefor | Active | 02-Nov-2021 | ||
| AU-2022383308-B2 | Antibody-drug conjugate intermediate comprising sn38 and preparation method therefor | Active | 02-Nov-2021 | ||
| CA-3228214-A1 | Antibody-drug conjugate intermediate comprising sn38 and preparation method therefor | Pending | 02-Nov-2021 | ||
| EP-4201429-A1 | Antibody-drug conjugate intermediate comprising sn38 and preparation method therefor | Active | 02-Nov-2021 | A61K47/68037 |
MabPlex Signals
MabPlex Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Tongji Innovation & Enterpreneurship Holdings | Corporation | Minority | ||
| China Merchants Securities | Asset Manager | Minority | ||
| Detong Capital | Venture Capital | Minority | ||
| Finnova Capital | Venture Capital | Minority | ||
| Gandao Investment Holding Company | Asset Manager | Minority |
MabPlex Investments (1)
MabPlex’s most recent deal was a Early Stage VC with CentryMed (Drug Discovery) for . The deal was made on 25-Sep-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| CentryMed (Drug Discovery) | 25-Sep-2020 | Early Stage VC | Drug Discovery |
MabPlex FAQs
-
When was MabPlex founded?
MabPlex was founded in 2013.
-
Where is MabPlex headquartered?
MabPlex is headquartered in Yantai, China.
-
What is the size of MabPlex?
MabPlex has 667 total employees.
-
What industry is MabPlex in?
MabPlex’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is MabPlex a private or public company?
MabPlex is a Private company.
-
What is MabPlex’s current revenue?
The current revenue for MabPlex is .
-
How much funding has MabPlex raised over time?
MabPlex has raised $128M.
-
Who are MabPlex’s investors?
Tongji Innovation & Enterpreneurship Holdings, China Merchants Securities, Detong Capital, Finnova Capital, and Gandao Investment Holding Company are 5 of 19 investors who have invested in MabPlex.
-
Who are MabPlex’s competitors?
Lonza Group, Bellen Chemistry, KBI BioPharma, AAPharmaSyn, and Fujifilm Diosynth Biotechnologies are some of the 16 competitors of MabPlex.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process